BRAFTOVI 50 mg, gélule

( ARTG ) Melanoma,Encorafenib in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test.,Colo‍‍‍‍‍‍​​​‍​​​​​​rectal Cancer (CRC),Encorafenib, in combination with cetuximab is indicated for the treatment of adult patients who have metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, and who have received prior systemic therapy.,Non-small cell lung cancer (NSCLC),Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.